Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
or

Portage Biotech Inc Ord (PRTG)

Portage Biotech Inc Ord (PRTG)
9.27 +0.18 (+1.98%) 15:23 ET [NASDAQ]
9.25 x 100 9.51 x 100
Realtime by (Cboe BZX)
9.25 x 100 9.51 x 100
Realtime 9.18 +0.09 (+0.99%) 09:17 ET
Quote Overview for Tue, Apr 22nd, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
9.01
Day High
15.82
Open 9.02
Previous Close 9.09 9.09
Volume 5,341,480 5,341,480
Avg Vol 3,630,966 3,630,966
Stochastic %K 49.54% 49.54%
Weighted Alpha -70.49 -70.49
5-Day Change +2.16 (+24.32%) +2.16 (+24.32%)
52-Week Range 2.10 - 23.01 2.10 - 23.01
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 9,534
  • Shares Outstanding, K 1,049
  • Annual Sales, $ 0 K
  • Annual Income, $ -75,340 K
  • EBIT $ -12 M
  • EBITDA $ -12 M
  • 60-Month Beta 0.54
  • Price/Sales N/A
  • Price/Cash Flow 0.97
  • Price/Book 11.83

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.07 +171.25%
on 03/25/25
Period Open: 4.15
15.82 -30.21%
on 04/22/25
+6.89 (+166.02%)
since 03/21/25
3-Month
3.77 +192.84%
on 01/23/25
Period Open: 4.10
15.82 -30.21%
on 04/22/25
+6.94 (+169.27%)
since 01/22/25
52-Week
2.10 +426.22%
on 08/14/24
Period Open: 5.94
23.01 -52.02%
on 09/18/24
+5.10 (+85.73%)
since 04/22/24

Most Recent Stories

More News
Portage Biotech’s After-Hours Surge On Preclinical Tumor Trial Data Sends Retail Optimism Sky-High

The company shared new data on PORT-7, a selective A2B receptor inhibitor, showing significant tumor growth inhibition in a mesothelioma model.

PRTG : 9.27 (+1.98%)
IWC : 106.41 (+3.71%)
Portage Biotech Stock More Than Doubles On Immunova Deal Potential: Retail Sees Big Opportunity

Under the terms of a proposed deal, Immunova, or its affiliate, would acquire the entire share capital of Portage subsidiary iOx Therapeutics.

PRTG : 9.27 (+1.98%)
Portage Biotech Inc. Notified by Nasdaq of Non-Compliance with Shareholders' Equity Requirement

Portage Biotech announces Nasdaq non-compliance notice; plans to submit compliance strategy by January 24, 2025.Quiver AI SummaryPortage Biotech Inc. has received a notice from Nasdaq indicating that it...

PRTG : 9.27 (+1.98%)
Portage Biotech Inc. Reports Q1 Fiscal 2025 Financial Results and Strategic Alternatives

Portage Biotech reports a net loss and continues exploring strategic alternatives while pausing a key clinical trial.Quiver AI SummaryPortage Biotech Inc. reported its financial results for the fiscal...

PRTG : 9.27 (+1.98%)
Portage Down on Announcing Alternatives

Portage Biotech Inc. (NASDAQ: PRTG) shares stumbled Friday, as the Westport, Conn.-based company a clinical-stage ...

PRTG : 9.27 (+1.98%)
UPDATE -- Portage Biotech Announces Results for Fiscal Year Ended March 31, 2022

--Company Continues to Execute on Core Business Model While Enhancing Value Proposition and Pipeline with Recent Transactions-- --Robust Pipeline Now...

PRTG : 9.27 (+1.98%)
Portage Biotech Announces Results for Fiscal Year Ended March 31, 2022

--Company Continues to Execute on Core Business Model While Enhancing Value Proposition and Pipeline with Recent Transactions-- --Robust Pipeline Now...

PRTG : 9.27 (+1.98%)
Portage Biotech Acquires Outstanding Minority Interest of Invariant Natural Killer T cell (iNKT) Agonist Platform

Portage now holds 100% ownership of iOx Therapeutics Ltd., buying out remainder of equity in exchange for PRTG stock...

PRTG : 9.27 (+1.98%)
Portage Biotech Bolsters Pipeline with Acquisition of Four Candidates Targeting the Adenosine Pathway

Acquires two clinical-stage, best in class adenosine compounds, and two preclinical assets for approximately $21 million upfront consideration Rob...

PRTG : 9.27 (+1.98%)
Portage Biotech Summarizes Data Presented at ASCO 2022 Annual Meeting Including Updates from Ongoing PORT-2 Study

Preliminary data from the Phase 1/2 trial of PORT-2 demonstrates favorable safety and tolerability as a monotherapy with translational data supporting its...

PRTG : 9.27 (+1.98%)

Business Summary

Portage Biotech Inc. is a clinical stage immuno-oncology company focused on overcoming immune resistance. The company source, nurture and develop therapies for a variety of cancers. Its drug development pipeline portfolio encompasses products or technologies with established scientific rationales, including...

See More

Key Turning Points

3rd Resistance Point 11.99
2nd Resistance Point 10.90
1st Resistance Point 9.99
Last Price 9.27
1st Support Level 7.99
2nd Support Level 6.90
3rd Support Level 5.99

See More

52-Week High 23.01
Fibonacci 61.8% 15.02
Fibonacci 50% 12.55
Fibonacci 38.2% 10.09
Last Price 9.27
52-Week Low 2.10

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Unlock High-Probability Trade Setups: Master Fractals & Time Frames Like a Pro